WESTON (dpa-AFX) - Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) on Friday reported positive long-term data from the Phase 1/2a and open-label extension studies evaluating zorevunersen in patients with Dravet syndrome, a rare, severe form of epilepsy that begins in infancy.
The companies said treatment with zorevunersen, administered in addition to standard anti-seizure medications, produced sustained reductions in seizure frequency, increased seizure-free days, and improvements in cognition, behavior and overall quality of life.
The findings were presented at the 2025 American Epilepsy Society Annual Meeting in Atlanta, Georgia.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
